Provided by Tiger Fintech (Singapore) Pte. Ltd.

Citius Pharmaceuticals, Inc.

1.08
+0.167418.34%
Post-market: 1.130.0500+4.63%19:59 EDT
Volume:2.91M
Turnover:3.19M
Market Cap:12.07M
PE:-0.19
High:1.24
Open:0.9380
Low:0.8822
Close:0.9126
Loading ...

Citius Pharmaceuticals Inc: Permanent J-Code (J9161) Expected to Be Effective April 1, 2025

THOMSON REUTERS
·
06 Feb

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

PR Newswire
·
06 Feb

BRIEF-Citius Pharmaceuticals Announces $3 Mln Registered Direct Offering

Reuters
·
08 Jan

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
08 Jan

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

PR Newswire
·
08 Jan

Citius Pharmaceuticals Shares Rise After Announcing Plans for Lymphir Launch

MT Newswires Live
·
08 Jan

BRIEF-Citius Pharmaceuticals And Citius Oncology Highlight Lymphir Commercial Launch Planned For First Half Of 2025

Reuters
·
07 Jan

Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25

TIPRANKS
·
07 Jan

Citius Pharmaceuticals and Citius Oncology Highlight Lymphir Commercial Launch Planned for First Half of 2025

THOMSON REUTERS
·
07 Jan

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

PR Newswire
·
07 Jan

Citius Oncology to explore strategic alternatives

TipRanks
·
07 Jan

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
07 Jan

Citius Oncology Retains Jeffries to Consider Strategic Alternatives

MT Newswires Live
·
06 Jan

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

THOMSON REUTERS
·
06 Jan

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

PR Newswire
·
06 Jan

Citius Pharmaceuticals Raised to Buy From Hold by D. Boral Capital

Dow Jones
·
30 Dec 2024

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

TIPRANKS
·
30 Dec 2024

Reported Friday, Citius Pharmaceuticals FY24 EPS $(5.97) Down From $(5.57) YoY; Cash $3.3M

Benzinga
·
30 Dec 2024

Citius Pharma Reports 2024 Financial Results and Business Update

TipRanks
·
30 Dec 2024

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
28 Dec 2024